GSK appoints Emma Walmsley as CEO
Published on 20/09/16 at 09:45am
Photo Credit: GlaxoSmithKline/PA
GlaxoSmithKline, the UK’s biggest drugs company, has appointed Emma Walmsley as its new CEO. Walmsley will step into the vacancy left by current CEO Sir Andrew Witty who will step down in March 2017.
Walmsley joined the company in 2010 and oversees its consumer healthcare division. She had previously served at L’Oreal for 17 years, working in the UK, Europe, China and the US. She now becomes the most powerful woman in the FTSE100 and one of just six female chief executives.
Hampton said: “Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare.”
Walmsley said: “I am delighted and honoured to be appointed GSK’s next CEO. I’m looking forward to working with Andrew and other leaders over the next few months to ensure a smooth handover and to develop plans for 2017 and beyond.”
Matt Fellows
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
